JAK1 and dengue disease: This will be the first trial of immunomodulation in dengue using biomarker-based enrichment for patient selection, and we hope that platforms to evaluate other host-directed therapeutics, such as the Janus kinase 1/2 inhibitor Baricitinib, will follow [19].